Skip to main content
    P

    Pacira BioSciences, Inc. (PCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $36.33
    -0.07 (-0.19%)

    Market Cap: $1.45B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(27/39)
    Avg Surprise
    +41.09%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.73
    Range$0.50 - $0.82
    9 analysts
    EPS RevisionsNo revisions (7d)
    2
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$0.76-3.6%
    60d ago$0.76-3.6%
    30d ago$0.71+2.8%
    7d ago$0.72+1.0%
    Current$0.73
    Revenue Consensus
    $183M
    Range$177M - $189M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.95
    Range$0.77 - $1.05
    9 analysts
    Revenue Consensus
    $207M
    Range$200M - $212M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.95---
    Sep 26EST
    		-$0.73---
    Jun 26
    Reported Aug 4
    		$0.44$0.27+62.96%Beat-40.5%
    Mar 26
    Reported Apr 30
    		$0.60$0.56+7.14%Beat-3.2%
    Dec 25
    Reported Feb 26
    		$0.32$0.60-46.67%Miss-64.8%
    Sep 25
    Reported Nov 6
    		$0.70$0.65+7.69%Beat-11.4%
    Jun 25
    Reported Aug 5
    		$0.74$0.71+4.23%Beat-16.9%
    Mar 25
    Reported May 8
    		$0.62$0.60+3.33%Beat+0.0%
    Dec 24
    Reported Feb 27
    		$0.91$0.83+9.60%Beat+2.2%
    Sep 24
    Reported Nov 6
    		$0.79$0.70+12.86%Beat+9.7%
    Jun 24
    Reported Jul 30
    		$0.89$0.70+27.14%Beat+14.1%
    Mar 24
    Reported May 7
    		$0.62$0.62+0.00%Beat+17.0%
    Dec 23
    Reported Feb 29
    		$0.89$0.87+2.30%Beat+11.2%
    Sep 23
    Reported Nov 2
    		$0.72$0.78-7.69%Miss+12.5%
    Jun 23
    Reported Aug 2
    		$0.78$0.76+2.63%Beat+52.9%
    Mar 23
    Reported May 3
    		$0.53$0.62-14.52%Miss-17.2%
    Dec 22
    Reported Feb 28
    		$0.80$0.83-3.61%Miss-17.5%
    Sep 22
    Reported Nov 3
    		$0.64$0.76-15.79%Miss-11.1%
    Jun 22
    Reported Aug 3
    		$0.51$0.85-40.00%Miss-33.8%
    Mar 22
    Reported May 4
    		$0.64$0.83-22.89%Miss+20.8%
    Dec 21
    Reported Feb 24
    		$0.97$0.90+7.78%Beat+11.5%
    Sep 21
    Reported Nov 3
    		$0.72$0.65+10.77%Beat+5.9%
    Jun 21
    Reported Aug 3
    		$0.77$0.74+4.05%Beat+541.7%
    Mar 21
    Reported May 4
    		$0.53$0.63-15.87%Miss+0.0%
    Dec 20
    Reported Feb 25
    		$0.87$0.81+7.41%Beat+55.4%
    Sep 20
    Reported Oct 29
    		$0.68$0.65+4.62%Beat+41.7%
    Jun 20
    Reported Aug 6
    		$0.12$0.09+33.33%Beat-70.7%
    Mar 20
    Reported May 7
    		$0.53$0.30+76.67%Beat+140.9%
    Dec 19
    Reported Feb 20
    		$0.56$0.44+27.27%Beat+19.1%
    Sep 19
    Reported Nov 7
    		$0.48$0.33+45.45%Beat+54.8%
    Jun 19
    Reported Aug 8
    		$0.41$0.34+20.59%Beat+70.8%
    Mar 19
    Reported May 2
    		$0.22$0.26-15.38%Miss+1000.0%
    Dec 18
    Reported Feb 28
    		$0.47$0.28+67.86%Beat+23.7%
    Sep 18
    Reported Nov 1
    		$0.31$0.08+287.50%Beat+181.8%
    Jun 18
    Reported Aug 2
    		$0.24$0.07+242.86%Beat+318.2%
    Mar 18
    Reported May 3
    		$0.02$0.03-33.33%Miss+110.5%
    Dec 17
    Reported Feb 28
    		$0.38$0.10+280.00%Beat+322.2%
    Sep 17
    Reported Nov 8
    		$0.11$-0.07+257.14%Beat-
    Jun 17
    Reported Aug 2
    		$-0.11$-0.05-120.00%Miss-
    Mar 17
    Reported May 4
    		$-0.19$-0.04-375.00%Miss-
    Dec 16
    Reported Mar 1
    		$0.09$0.01+800.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio17.64EV/EBITDA15.63x
    Price/FCF7.99xFCF Yield12.52%
    Profitability
    Profit Margin1.96%Operating Margin6.17%
    ROE2.05%ROIC1.56%
    Financial Health
    Debt/Equity0.54xInterest Coverage1.18x
    Current Ratio5.04xQuick Ratio3.94x
    Trading Statistics
    Beta0.25Avg Volume2.32M
    52-Week High$36.4652-Week Low$18.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$31.83
    SMA 20$28.41
    SMA 50$26.36
    SMA 200$24.19
    EMA 10$32.97
    EMA 20$30.18
    EMA 50$27.48
    EMA 200$25.10

    MACD

    Line: 2.95Signal: 1.74Hist: 1.21

    ADX

    ADX: 36.0+DI: 56.1-DI: 6.7

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down12.0
    PSAR$30.40

    Bollinger Bands

    Upper Band$39.09
    Lower Band$17.73
    %B Position7521%(Upper)
    Band Width0.87

    RSI (14-Day)

    Overbought
    84.0

    Momentum Oscillators

    Stoch %K98.4
    Stoch %D98.8
    Williams %R-2.8
    ROC (10d)45.3%
    Momentum11.32
    CCI (20d)112.1
    MFI (14d)82.3

    Volatility Measures

    ATR (14d)$1.13(3.1%)
    StdDev (20d)5.34
    Hist Vol158.8%(High)

    Volume Flow

    VWAP$36.44
    OBV36.6M
    AD Line1.2M
    CMF (20d)0.030

    Volume Metrics

    Avg Vol (20d)2.5M
    Vol Ratio0.8x
    VWMA (20d)$34.64

    Pivot Points

    R3$36.65
    R2$36.57
    R1$36.48
    Pivot Point$36.40
    S1$36.31
    S2$36.23
    S3$36.14

    Advanced Oscillators

    TSI55.42
    Ultimate Osc81.7
    KST237.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$192.40M$177.38M$196.87M$179.52M$181.10M$168.92M$187.25M$168.57M$178.02M$167.12M$181.24M$163.93M
    Cost of Revenue$44.16M$36.41M$40.30M$34.28M$40.87M$34.31M$39.89M$38.86M$44.26M$47.42M$47.69M$39.75M
    Gross Profit$148.24M$140.96M$156.57M$145.24M$140.23M$134.62M$147.37M$129.71M$133.76M$119.70M$133.55M$124.18M
    Operating Expenses$143.97M$134.06M$154.23M$138.88M$131.73M$132.63M$122.66M$269.24M$105.52M$106.49M$100.38M$106.45M
    R&D$30.24M$28.07M$37.80M$25.97M$28.20M$25.34M$23.90M$19.10M$20.34M$18.24M$19.46M$20.83M
    SG&A$91.81M$93.94M$101.61M$91.80M$88.58M$86.78M$79.61M$74.33M$68.13M$72.03M$65.80M$67.95M
    Operating Income$4.27M$6.90M$2.34M$6.36M$8.50M$1.99M$24.70M$-139,527,000$28.24M$13.21M$33.17M$17.72M
    Interest Income$1.94M$1.93M$2.29M$8.53M$5.01M$6.89M$5.55M$5.48M$4.75M$3.90M$3.42M$2.77M
    Interest Expense$3.62M$3.70M$3.89M$5.26M$4.70M$4.58M$4.68M$4.69M$-3,634,000$3.32M$3.39M$3.46M
    Income Before Tax$2.56M$5.00M$571,000$9.52M$-1,927,000$8.71M$25.53M$-138,856,000$36.58M$13.64M$33.72M$16.60M
    Income Tax Expense$-2,098,000$2.08M$-1,066,000$4.09M$2.92M$3.89M$9.48M$4.61M$17.70M$4.66M$8.85M$5.74M
    Net Income$4.65M$2.92M$1.64M$5.43M$-4,847,000$4.81M$16.04M$-143,466,000$18.89M$8.98M$24.87M$10.86M
    EBITDA$26.41M$28.11M$19.16M$28.13M$24.61M$26.52M$39.34M$-118,533,000$47.85M$32.18M$48.30M$36.44M
    EBIT$4.23M$6.77M$2.17M$6.25M$-2,240,000$6.39M$24.65M$-139,649,000$28.20M$13.05M$33.68M$17.30M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PCRX

    News

    Royal Bank of Canada lifts target for Pacira BioSciences stock to USD 36.50

    Royal Bank of Canada has increased its price target for Pacira BioSciences (PCRX) stock to USD 36.50 from USD 25.00...

    ad-hoc-news.de•10/15/26•Bullish

    Seven investors report stakes below 5% in Pacira BioSciences (PCRX).

    A Schedule 13D amendment for Pacira BioSciences (PCRX) indicates that seven reporting persons, including DOMA Perpetual Capital Management LLC and The John Templeton Foundation...

    Stock Titan•10/14/26•Neutral

    Form 13D/A Pacira BioSciences For: 13 October By Investing.com

    This article announces the filing of Form 13D/A for Pacira BioSciences on October 13th, as reported by Investing.com. It is a brief news item indicating a regulatory filing related to the company. The content primarily...

    Investing.com India•10/13/26•Neutral

    Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

    Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. for $36.50 per share in cash. The law firm is examining whether this consideration...

    Business Wire•10/12/26•Somewhat-Bearish

    SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)

    Monteverde & Associates PC, a class action firm, has announced an investigation into Pacira BioSciences, Inc. (NASDAQ...

    PR Newswire•10/11/26•Somewhat-Bearish

    PCRX Valuation and Fair Value

    P/E
    17.6x
    Forward P/E
    6.3x
    EV/EBITDA
    15.6x
    P/FCF
    8.0x
    PEG
    11.2x
    P/B
    2.1x
    See GNG's fair value

    PCRX Profitability: Margins, ROIC and FCF

    Gross margin
    79.2%
    Operating margin
    6.2%
    Net margin
    2.0%
    ROIC
    1.6%
    ROE
    2.1%
    FCF margin
    24.1%
    FCF yield
    12.5%

    PCRX Competitors

    CompanyTicker
    Uniqure NVQURE
    Healthcare Services Group IncHCSG
    Immunocore Holdings LtdIMCR
    Pennant Group IncPNTG
    Certara IncCERT
    AMN Healthcare Services IncAMN
    UltragenyxRARE
    Nutex Health IncNUTX

    Sector: Healthcare

    PCRX Analyst Ratings

    Consensus
    Hold
    Analysts
    9
    Strong Buy
    1
    Buy
    4
    Hold
    3
    Sell
    0
    Strong Sell
    1

    PCRX Bull Case vs Bear Case

    Bull case

    • PCRX converts 24.1% of revenue into free cash flow.
    • PCRX beat EPS estimates in 87.5% of its last 8 reported quarters.

    PCRX Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    7.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.73
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 3 down

    Frequently Asked Questions About PCRX

    Does PCRX pay dividends?

    Pacira BioSciences, Inc. (PCRX) does not currently pay a regular dividend.

    What is PCRX's P/E ratio?

    Pacira BioSciences, Inc. has a price-to-earnings (P/E) ratio of 17.64.

    What is PCRX's market cap?

    Pacira BioSciences, Inc. (PCRX) has a market capitalization of $1.45B with a current stock price of $36.33.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In